Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Bluebird Bio (BLUE)

Bluebird Bio (BLUE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,441,440
  • Shares Outstanding, K 66,373
  • Annual Sales, $ 44,670 K
  • Annual Income, $ -789,610 K
  • 60-Month Beta 1.89
  • Price/Sales 12.32
  • Price/Cash Flow N/A
  • Price/Book 2.28
Trade BLUE with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -3.04
  • Number of Estimates 14
  • High Estimate -2.45
  • Low Estimate -3.46
  • Prior Year -4.04
  • Growth Rate Est. (year over year) +24.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
42.85 +17.92%
on 01/04/21
53.68 -5.87%
on 01/12/21
+6.17 (+13.91%)
since 12/15/20
3-Month
41.50 +21.76%
on 12/11/20
59.32 -14.82%
on 11/04/20
-4.75 (-8.59%)
since 10/15/20
52-Week
38.95 +29.73%
on 03/17/20
99.36 -49.14%
on 01/17/20
-43.19 (-46.08%)
since 01/15/20

Most Recent Stories

More News
Harpoon's (HARP) Multiple Myeloma Candidate Gets Orphan Drug Tag

Harpoon (HARP) gets Orphan Drug designation by the FDA for HPN217 for the treatment of multiple myeloma.

JNJ : 160.30 (-0.22%)
BMY : 66.54 (+0.79%)
BLUE : 50.53 (-2.55%)
HARP : 23.40 (+9.55%)
Biotech Stock Roundup: Updates From REGN, GILD & VIR, CVAC Teams Up With BAYRY

The biotech sector was in focus last week with guidance updates from quite a few biotechs like Gilead (GILD). Additionally, updates on coronavirus treatments from Regeneron (REGN) and Vir (VIR) were in...

REGN : 517.93 (unch)
GILD : 63.33 (+1.49%)
BLUE : 50.53 (-2.55%)
VIR : 39.31 (+7.73%)
CVAC : 100.35 (-0.24%)
Global Bacterial and Plasmid Vectors Market Report 2020-2030 Featuring Sigma-Aldrich, ATUM, QIAGEN, Promega, Thermo Fisher Scientific, GenScript Biotech, Takara Bio, and New England Biolabs

, /PRNewswire/ -- The report has been added to offering.

BLUE : 50.53 (-2.55%)
GNNSF : 1.3800 (-2.13%)
TKBIF : 26.3600 (-0.53%)
bluebird (BLUE) to Spin Off Oncology Unit Into Separate Entity

bluebird (BLUE) to separate its severe genetic disease and oncology businesses into different and independent publicly traded companies. Shares up.

BMY : 66.54 (+0.79%)
HALO : 47.43 (+0.81%)
BLUE : 50.53 (-2.55%)
RCUS : 36.98 (-4.76%)
bluebird bio to Separate Oncology Business into Independent Company

--Separation designed to unlock value through improved operational execution, organizational focus, tailored capital allocation, and enhanced strategic optionality

BLUE : 50.53 (-2.55%)
Global Cell and Gene Therapy Market Report 2020 Featuring Major Players - Gilead Sciences, BMS, Novartis, Amgen, Merck, Organogenesis, Dendreon, Vericel, Bluebird Bio and Fibrocell Science

, /PRNewswire/ -- The report has been added to offering.

AMGN : 245.49 (+1.58%)
BLUE : 50.53 (-2.55%)
BMY : 66.54 (+0.79%)
GILD : 63.33 (+1.49%)
MRK : 83.38 (+1.47%)
NVS : 95.63 (+1.07%)
ONCE : 110.05 (-3.10%)
SmarTrend Watching for Potential Rebound in Shares of Bluebird Bio Inc After 3.67% Loss

Bluebird Bio Inc (NASDAQ:BLUE) traded in a range yesterday that spanned from a low of $43.85 to a high of $45.98. Yesterday, the shares fell 3.7%, which took the trading range below the 3-day low of...

BLUE : 50.53 (-2.55%)
First Week of BLUE August 2021 Options Trading

Investors in bluebird bio Inc saw new options become available this week, for the August 2021 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the...

BLUE : 50.53 (-2.55%)
J&J (JNJ) Begins Rolling BLA Filing of Multiple Myeloma Drug

J&J (JNJ) initiates the rolling submission of its BLA to the FDA for BCMA CAR-T therapy, ciltacabtagene autoleucel to treat adults with relapsed/refractory multiple myeloma.

IRWD : 11.03 (-2.65%)
JNJ : 160.30 (-0.22%)
BMY : 66.54 (+0.79%)
BLUE : 50.53 (-2.55%)
Global Gene Therapy Market Report 2020-2030 Featuring Novartis, Bluebird Bio, Spark Therapeutics, Audentes Therapeutics, Voyager Therapeutics, UniQure, Celgene, Cellectis and Sangamo Therapeutics

, /PRNewswire/ -- The report has been added to offering.

BOLD : 59.97 (-0.02%)
BLUE : 50.53 (-2.55%)
CELGZ : 0.47 (+2.15%)
CMVLF : 31.0200 (+3.16%)
GSK : 38.47 (+0.81%)
NVS : 95.63 (+1.07%)
ONCE : 110.05 (-3.10%)
VYGR : 8.50 (-4.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio,...

See More

Key Turning Points

3rd Resistance Point 55.34
2nd Resistance Point 53.81
1st Resistance Point 52.83
Last Price 50.53
1st Support Level 50.32
2nd Support Level 48.79
3rd Support Level 47.81

See More

52-Week High 99.36
Fibonacci 61.8% 76.28
Fibonacci 50% 69.15
Fibonacci 38.2% 62.03
Last Price 50.53
52-Week Low 38.95

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar